

Investor Newsletter

Issue 08 2020



MicroPort® CardioFlow Receives Approval for VitaFlow® Aortic Valve System in Argentina

Shanghai MicroPort® CardioFlow Medtech Co., Ltd. (“MicroPort® CardioFlow”) is pleased to announce it has received regulatory approvals for its VitaFlow® Aortic Valve System (“VitaFlow® System”), Alwide™ Balloon Catheter, and Alpass™ Introducer Set from ANMAT of Argentina. The VitaFlow® Aortic Valve System with a self-expanding frame with bovine pericardial leaflets is the first of its kind to be approved in China. This also marked the first time a product developed by MicroPort® CardioFlow, receives approval in a market outside of China.

The VitaFlow® System has won praise from healthcare professionals since it was granted a registration certificate from the National Medical Products Administration of China (NMPA) in July 2019. Over the past year, use of the device has grown rapidly and brought benefit to many patients with aortic valvular diseases. As Argentina is the most developed market for Transcatheter Aortic Valve Replacement (TAVR) in South America, this approval marks a major milestone in MicroPort® CardioFlow’s overseas development. In the future, MicroPort® CardioFlow will further expedite our expansion in the international market to ensure more patients and doctors have access to a high-quality solution to aortic valvular diseases.





MicroPort® Access Receives Approvals for PCI Accessory Products in Egypt

Shanghai MicroPort® Access MedTech Co., Ltd. (“MicroPort® Access”) is pleased to announce it has recently received regulatory approvals for its PCI accessory products from CAPA of Egypt. This marked its first approval for launch in an African country.


Prior to approval in Egypt, these PCI accessory products launched in Asian and South American countries including Thailand, Indonesia, Brazil and Argentina. The approval in Egypt marked its entry in the African market for the first time and a breakthrough in overseas market expansion. These devices are also well suited to use along with the Firehawk® Rapamycin Target Eluting Coronary Stent System developed by MicroPort® and launched in Egypt. Collectively the MicroPort® devices will provide an improved integrated PCI therapeutic solution for doctors and their patients.

MicroPort® Access Receives Approvals for Angiography Guidewire and Angiography Catheter in Brazil

Shanghai MicroPort® Access MedTech Co., Ltd. (“MicroPort® Access”) is pleased to announce it has recently received regulatory approvals for its Angiography Guidewire and Angiography Catheter from ANVISA of Brazil.

Prior to approval in Brazil, the two devices successfully have launched in China and become well established in surgical practice. The Angiography Guidewire is the result of a collaboration between doctors and engineers. Adopting the pioneering guidewire tip structure allows the distal end of both the main wire and coil wire to be smaller. This significantly improves the device’s maneuverability in challenging cases where anatomical structures are heavily complex. The Angiography Catheter offers surgeons most common 5F and 6F specifications required in angiography procedures whilst also providing both left and right support type for additional flexibility.

Previously, MicroPort® Access had received approvals for its Inflation Device, Y Connector, Pressure Monitoring Tubings, and Manifolds in Brazil. These latest approvals for Angiography Guidewire and Angiography Catheter lay a solid groundwork for the company’s further expansion in the South American market. These devices are also well-suited to be used along with the Firehawk® Rapamycin Target Eluting Coronary Stent System developed by MicroPort®. Collectively the MicroPort® devices will provide an improved integrated PCI therapeutic solution for doctors and their patients.



MicroPort and subsidiary MicroPort® MedBot Jointly Announces External Funding Agreement and Major **Strategic Investors**

On August 31, 2020, MicroPort Scientific Corporation (“MicroPort®”) and MicroPort MedBot (Shanghai) Co., Ltd. (“MicroPort® MedBot”), a MicroPort® subsidiary, jointly entered into a 3 billion yuan funding agreement. According to the agreement, the funding consists of transferring a portion of MicroPort®’s shareholding in MicroPort® MedBot, which is valued at 1.5 billion yuan, and a direct additional investment worth 1.5 billion yuan in the subsidiary. The agreement has brought in the renowned strategic investors including Hillhouse Capital, CPE, Biolink Capital, Ground Flight Investment, and Efund. After concluding this round of funding, MicroPort® MedBot will remain a subsidiary controlled by MicroPort®.




Since 2014, MicroPort® MedBot has been engaged in the research and development and the commercialization of break-through surgical robotic systems. The company is committed to addressing the most cutting-edge development needs of minimally invasive surgery, and providing innovatively integrated intelligent surgical solutions that can save patients’ lives or improve their quality of life. After years of R&D innovation and accumulation of industry expertise, the company has developed into a technology innovation company that has mastered core competencies needed across the whole supply chain of underlying technologies that are the prerequisites of the surgical robotic systems, with multi-disciplinary integration and platform expansion capabilities such as optics, mechanics, electronics, control, software, computing and angiography. MicroPort® MedBot’s current business completely covers the five “golden segments” comprising endoscope, orthopedics, vascular intervention, natural orifice and percutaneous puncture. The company’s three flagship systems in respective niche segments, namely Toumai™ Endoscopic Surgical Robotic System, Skywalker™ Orthopedic Surgery Navigation and Positioning System and DFVision™ 3D Electronic Laparoscope, have been granted entries into the “Green Channel” for innovative medical devices under a program of the National Medical Products Administration (NMPA). The company has an international team with outstanding talents and rich experience in robotic research and development, and medical device commercialization. With more than 250 domestic and international patents, the company has built a multi-segment, forward-looking and high-value intellectual property system for domestic surgical robotic systems.

MicroPort® EP Announces New **Strategic Investors**

Shanghai MicroPort® EP MedTech Co., Ltd. ("MicroPort® EP") announced that it has officially entered into a 300 million RMB (US\$43 million) funding agreement with four renowned strategic investors, including CPE ("CITIC Private Equity"), Grand Flight Investment, E Fund Management and Shanghai Pudong Kechuang Group. Upon completion of the investment, the valuation of MicroPort® EP will reach 4.8 billion RMB.

Dr. Yiyong Sun, MicroPort® EP President, commented, "This round of funding will bring in essential financial support for the company's development of new products and market expansion to help our business enter a new stage of rapid development. As the only Chinese company able to provide integrated electrophysiological solutions that combine active with inactive and devices with equipment, MicroPort® EP will continue to adhere to the rationale featuring unrelenting exploration, innovation and pursuit of excellent quality. MicroPort® EP will create high quality and accessible therapeutic solutions for patients and doctors. In addition, MicroPort® hopes to be able to drive the rapid development of the electrophysiological sector in China, when the company helps increase the effective treatment rates of arrhythmia patients and reduce the burden on the national health insurance program."



MicroPort® Announces Interim Results for the Six Months Ended June 30, 2020

MicroPort Scientific Corporation (the “Company”, or “MicroPort”, Stock code: 00853) announced the interim results of the Company and its subsidiaries (collectively, the “Group”) for the six months ended June 30, 2020 (the “reporting period”) on August 27. During the first half of 2020, in the face of the COVID-19 epidemic spread worldwide, the Group optimally allocated its global resources to the fullest extent and took safe, highly efficient and innovative measures to implement production, operations and marketing activities in an orderly manner. The Group’s global business started to hold steady and pick up in the second quarter. Meanwhile, the Group benefitted from the adequate cash raised from the capital market by itself and its subsidiaries to further strengthen its balance sheet and accelerate the business expansion and long-term development of the business segments, thus building and enhancing the overall competitiveness of the Group.



During the reporting period, the Group recorded a revenue of US\$306.9 million, representing a year-over-year decline of 19.7% (excluding the foreign exchange impact), and a gross profit margin of 70.9%. The loss attributable to the Group’s equity shareholders was US\$65.6 million. As of July 2020, the Group, its subsidiaries, and affiliated companies raised combined funds of about RMB 4.07 billion.

MicroPort (00853.HK) Wins Addition into **MSCI** Hong Kong Index

MicroPort Scientific Corporation (00853.HK) will become a constituent stock in the MSCI Hong Kong Index and be removed from the MSCI Hong Kong Small Cap Index after MSCI Inc., the world's renowned index construction and maintenance company, recently announced its latest quarterly index review results. The change will take effect after trading hours on August 31, 2020.

MSCI Inc. is one of the most influential provider of indexes in the world. The MSCI Indexes are one of the most widely used indexes, on which global investment portfolio managers base their investment decisions. The MSCI Hong Kong Index is designed to measure the performance of the large and mid-cap segments of the Hong Kong market. With 40 constituents, the index covers approximately 85% of the free float-adjusted market capitalization of the Hong Kong equity universe. The addition into the index requires qualified market value, outstanding shares and stock liquidity of the listed companies.

Since MicroPort Scientific Corporation was listed on the Hong Kong Stock Exchange in 2010, the Company achieved continuous and stable expansion in business scale and rapid growths in key business segments and core products, benefitting from the effective implementation of a globalization and diversification strategy. The addition into the MSCI Hong Kong Index proved that the Company is widely recognized by the capital market. It also demonstrated the Company's long-term development strength and growing market capitalization. The Company will continue to unrelentingly enhance its innovation and R&D capabilities. The Company will also enrich a global operational strategy based on localization to achieve its sustainable development.



Investor Newsletter

Issue **08** 2020



For more information, please contact:

Martin Sun

Chief Financial Officer
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com

Leanne Li

Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com